Glycoconjugation Processes and Compositions
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/IB2013/056597, filed Aug 12, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,950,054 | Glycoconjugation Processes and Compositions In force · High confidence | Pfizer Inc. | In force | High confidence | ||
| US 10,583,187 | Glycoconjugation Processes and Compositions In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | ||
| US 11,110,160 | Glycoconjugation Processes and Compositions In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | ||
| US 11,723,965 | Glycoconjugation Processes and Compositions In force · Low confidence | Pfizer Inc. | In force | Low confidence | ||
| US 12,447,203 | Glycoconjugation Processes and Compositions In force · Medium confidence | Pfizer Inc. | In force | Medium confidence | ||
| US 9,517,274 | Glycoconjugation Processes and Compositions In force · High confidence | Pfizer Inc. | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.